Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Halda Therapeutics

Explore full profile

Precision oncology therapies targeting cancer via RIPTAC™ chimera

New Haven, United StatesFounded 2018Biotech & Life Sciences
Valuation $2.5–5B Last recorded · 2025
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Halda Therapeutics and the history behind them.

About Halda Therapeutics

Halda is a biotechnology company focused on developing a new class of precision medicines known as RIPTAC therapeutics to combat cancer. These innovative drugs work by holding two proteins together: one that is tumor-specific and another that performs an essential function, resulting in the selective killing of cancer cells. Halda operates in the biotechnology and pharmaceutical market, primarily serving patients and healthcare providers in the oncology sector. The company's business model revolves around the research, development, and commercialization of these novel therapeutics. Revenue is generated through the sale of these drugs, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. Halda's leadership team, including CFO Scott Phillips, brings extensive experience in finance and biotech, ensuring robust financial management and strategic growth.

Source: Dealroom company data

At a glance

Founded
2018
Headquarters
New Haven, United States
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Latest news

Press, funding announcements and product moves mentioning Halda Therapeutics.

See all news

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • Frazier Life Sciences
  • Access Industries
  • Canaan
  • Connecticut Innovations
  • Taiho Pharma
  • Vida Ventures
  • RA Capital Management
  • Elm Street Ventures
  • Boxer Capital
  • Deep Track Capital

Series B and later11 investors entered at this stage

  • Taiho Pharma
  • RA Capital Management
  • Deep Track Capital
  • Frazier Life Sciences
  • Access Industries
  • Yale University
  • Elm Street Ventures
  • Connecticut Innovations
  • Vida Ventures
  • Canaan
  • Boxer Capital
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
7.1K monthly visits
across markets
🇺🇸 United States98.6%
🇳🇱 Netherlands1.4%
Top 2 markets shown

Patents

Estimated portfolio value
$246k

14 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Halda Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Halda Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.